GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (MIL:1VRTX) » Definitions » Price-to-Tangible-Book

Vertex Pharmaceuticals (MIL:1VRTX) Price-to-Tangible-Book : 9.20 (As of Dec. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Vertex Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-12-14), Vertex Pharmaceuticals's share price is €441.00. Vertex Pharmaceuticals's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was €47.93. Hence, Vertex Pharmaceuticals's Price to Tangible Book Ratio of today is 9.20.

The historical rank and industry rank for Vertex Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

MIL:1VRTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.72   Med: 10.31   Max: 53.85
Current: 8.76

During the past 13 years, Vertex Pharmaceuticals's highest Price to Tangible Book Ratio was 53.85. The lowest was 5.72. And the median was 10.31.

MIL:1VRTX's Price-to-Tangible-Book is ranked worse than
83.49% of 1205 companies
in the Biotechnology industry
Industry Median: 2.81 vs MIL:1VRTX: 8.76

A closely related ratio is called PB Ratio. As of today, Vertex Pharmaceuticals's share price is €441.00. Vertex Pharmaceuticals's Book Value per Sharefor the quarter that ended in Sep. 2024 was €54.64. Hence, Vertex Pharmaceuticals's P/B Ratio of today is 8.07.


Vertex Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Vertex Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Price-to-Tangible-Book Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 6.61

Vertex Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.61 6.48 9.65 8.70

Competitive Comparison of Vertex Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Vertex Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Price-to-Tangible-Book falls into.



Vertex Pharmaceuticals Price-to-Tangible-Book Calculation

Vertex Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2024 )
=441.00/47.932
=9.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Vertex Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Headlines

No Headlines